Therapeutic Apheresis Market Research, 2035
The global therapeutic apheresis market size was valued at $1.3 billion in 2023, and is projected to reach $2.8 billion by 2035, growing at a CAGR of 6.7% from 2024 to 2035. The therapeutic apheresis market is driven by increase in prevalence of autoimmune diseases, neurological disorders, and blood-related conditions requiring plasma exchange and cytapheresis. For instance, according to an article published by American Society for Clinical Investigation in 2024, over 15 million people, or 4.6% of the U.S. population, were diagnosed with at least 1 autoimmune disease from January 1, 2011, to June 1, 2022. In addition, favorable reimbursement policies and expanding healthcare infrastructure contribute to the market expansion.
Key Takeaways
- On the basis of product type, the consumables segment dominated the global therapeutic apheresis market share in 2023.
- On the basis of procedure type, the therapeutic plasma exchange (TPE) segment dominated the global market in 2023. However, the photopheresis segment is anticipated to be the fastest-growing segment during the forecast period.
- On the basis of application, the hematology segment dominated the market in terms of revenue in 2023 and is expected to register the highest CAGR during the forecast period.
- On the basis of end user, the hospitals segment dominated the market in terms of revenue in 2023.
- North America dominated the market in terms of revenue in 2023. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Therapeutic apheresis is a medical procedure that involves the selective removal of specific components from a patients blood to treat various diseases and conditions. This process is used to eliminate harmful substances such as abnormal antibodies, excess lipids, or toxic elements while returning the remaining blood components to the patient. It includes different techniques such as plasmapheresis (plasma exchange), leukapheresis (white blood cell removal), thrombocytapheresis (platelet removal), and others. Therapeutic apheresis is widely used in managing autoimmune disorders, neurological diseases, hematological conditions, and metabolic disorders.
Market Dynamics
The therapeutic apheresis market size is experiencing significant growth driven by increase in prevalence of autoimmune disorders, neurological diseases, and hematological conditions that require blood component separation and purification. Rise in cases of conditions such as Guillain-Barr syndrome, myasthenia gravis, multiple sclerosis, and thrombotic thrombocytopenic purpura has led to growing demand for apheresis procedures. These techniques, including plasmapheresis, cytapheresis, and lipid apheresis, play a crucial role in removing harmful substances from the blood, providing effective treatment options for patients with chronic or life-threatening diseases. For instance, according to the National Cancer Institute, around 2 million new cases of cancer were diagnosed in the U.S. in 2024.
In addition, rise in technological advancements in apheresis devices further contributed to therapeutic apheresis market share. The development of automated and portable apheresis systems has improved efficiency, precision, and patient comfort, making procedures more accessible in both hospital and outpatient settings. Innovations such as selective adsorption columns and membrane filtration techniques have enhanced treatment efficacy, leading to increased adoption among healthcare providers.
Furthermore, favorable reimbursement policies and government initiatives supporting blood management and transfusion services are also driving the therapeutic apheresis market growth. In many countries, healthcare agencies and insurance providers are offering reimbursement for therapeutic apheresis procedures, encouraging hospitals and clinics to integrate these treatments into their services. Moreover, increasing awareness among patients and healthcare professionals about the benefits of therapeutic apheresis has contributed to higher treatment rates.
The therapeutic apheresis market growth is driven by the expanding applications of therapeutic apheresis beyond traditional indications, such as its use in sepsis management, organ transplantation, and oncology, are further fueling market demand. As clinical research continues to explore new therapeutic areas, the market is expected to witness sustained growth. In addition, rise in investments in healthcare infrastructure, especially in emerging economies, are creating new opportunities for market expansion, making therapeutic apheresis a vital component of modern medical treatment strategies.
However, high cost associated with apheresis procedures and equipment, makes it less accessible in low- and middle-income countries. The requirement for specialized infrastructure and trained professionals further adds to the overall treatment expense, restricting its availability in resource-limited settings. In addition, the complexity of the procedure increases the risk of complications such as infections, hypotension, and allergic reactions, leading to concerns about patient safety.
On the other hand, advancements in apheresis devices, including automated systems, improved membrane filtration, and selective adsorption technologies, are enhancing treatment precision and efficiency, making procedures more accessible and effective which provides an therapeutic apheresis market opportunity. In addition, rise in healthcare expenditures and government initiatives supporting blood transfusion and plasma exchange programs are fostering market expansion, particularly in emerging economies.
Segmental Overview
The therapeutic apheresis market is segmented on the basis of product type, procedure type, application, end user, and region. By product type, the market is classified into devices, consumables, and software. By procedure type, the market is segmented into therapeutic plasma exchange (TPE), photopheresis, low density lipid removal, stem cell harvest, and other procedures. By application, the market is classified into hematology, neurology, oncology, and others. By end user, the market is segmented into hospitals, blood centers, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By Product Type
The consumables segment dominated the market share in 2023 and is expected to register the highest CAGR during the forecast period. This is attributed to high demand for single-use apheresis kits, tubing sets, filters, and reagents required for each procedure. The recurring nature of these consumables in therapeutic apheresis procedures, coupled with the increasing volume of treatments for autoimmune disorders, hematological conditions, and neurological diseases, contributed to its significant market share.
By Procedure Type
The therapeutic plasma exchange (TPE) segment dominated the market share in 2023. This is attributed to widespread reliance on advanced imaging techniques such as CT scans, MRI, PET scans, and endoscopic ultrasound as the gold standard for pancreatic cancer detection and staging. The superiority of imaging in providing detailed visualization of pancreatic tumors, their size, location, and potential metastasis made it indispensable in the diagnostic process, further supporting the segment growth.
However, the photopheresis segment is expected to register the highest CAGR during the therapeutic apheresis market forecast period. This is attributed to its increasing adoption in treating autoimmune diseases, graft-versus-host disease (GVHD), and cutaneous T-cell lymphoma. Advancements in light-based immunomodulation therapies and expanding clinical applications further support the segment growth.
By Application
The hematology segment dominated the market share in 2023 and is expected to register the highest CAGR during the forecast period. This is attributed to rise in prevalence of hematological disorders, including leukemia, lymphoma, and sickle cell disease. Rise in demand for apheresis procedures, such as plasmapheresis and leukapheresis, for blood-related conditions is a key growth driver. In addition, rise in technological advancements in blood purification techniques and the growing adoption of automated apheresis systems further fueled market expansion. Furthermore, increasing awareness, improved healthcare infrastructure, and favorable reimbursement policies are encouraging the use of hematology-related therapeutic apheresis, contributing to sustained segment growth.
By End User
The hospitals segment dominated the market in terms of revenue in 2023 and is expected to continue growing due to the high volume of apheresis procedures conducted in hospital settings. This dominance is attributed to advanced healthcare infrastructure, which enables the management of complex treatments, including therapeutic apheresis for hematological, neurological, and autoimmune disorders. The presence of skilled healthcare professionals, specialized apheresis units, and access to cutting-edge technologies further support the market growth. In addition, hospitals benefit from favorable reimbursement policies and government funding, making them the preferred choice for patients undergoing apheresis procedures, thereby driving revenue generation in this segment.
By Region
The therapeutic apheresis industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in terms of revenue in 2023. The growth in this region is attributed to a well-established healthcare infrastructure, advanced medical technologies, and high adoption rate of apheresis procedures for various therapeutic applications. Rise in prevalence of hematologic disorders, autoimmune diseases, and neurological conditions has significantly increased the demand for therapeutic apheresis. Also, growing emphasis on personalized medicine and regenerative therapies, including stem cell transplantation, has further propelled market expansion.
Asia-Pacific is expected to grow at the highest rate during the forecast period owing to rise in prevalence of hematologic disorders, autoimmune diseases, and metabolic conditions, driving the demand for therapeutic apheresis. Increasing healthcare expenditure, coupled with improving healthcare infrastructure, is facilitating the adoption of advanced apheresis procedures across emerging economies.
Government initiatives and favorable policies supporting medical advancements and access to innovative therapies are further accelerating the market growth. The expanding presence of global market players, along with strategic partnerships and collaborations with regional healthcare providers, is enhancing the availability of apheresis devices and services. In addition, rise in number of clinical trials and research activities focused on blood component separation and regenerative medicine is contributing to the market expansion.
Competition Analysis
Key players such as Baxter International Inc. and Terumo Corporation have adopted partnership, agreement, and investment as key developmental strategies to improve the product portfolio of the therapeutic apheresis market. For instance, in May 2021, Baxter International Inc. announced the global launch of PrisMax 2, the latest version of the companies next-generation platform. PrisMax 2 is designed to help simplify delivery of continuous renal replacement therapy (CRRT) and other organ support therapies, while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU).
Recent Developments in Therapeutic Apheresis Industry
In November 2024, Terumo BCT announced a strategic partnership with Terumo Medical Products (Hangzhou) Co., Ltd., investing in its production facility located in the Qiantang District, Hangzhou, seeking to provide high-quality locally made medical products for the Chinese market.
In August 2023, Fresenius Kabi and Lupagen Inc. announced the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside. Under the terms of the agreement, Fresenius Kabi will provide their expertise in apheresis collection and automated cell processing equipment to advance Extracorporeal Cell and Gene Therapy Delivery System, which focuses on simplifying and reducing costs for cell and gene therapy through a bedside procedure.
In February 2024, Terumo announced a £1.5 million investment to enhance care for sickle cell disease patients in England. This funding will provide 25 red blood cell exchange devices, enabling patients to receive improved treatment closer to home.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the therapeutic apheresis market analysis from 2023 to 2035 to identify the prevailing therapeutic apheresis market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the therapeutic apheresis market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global therapeutic apheresis market trends, key players, market segments, application areas, and market growth strategies.
Therapeutic Apheresis Market Report Highlights
| Aspects | Details |
 Market Size By 2035 | USD 2.8 billion |
 Growth Rate | CAGR of 6.7% |
 Forecast period | 2023 - 2035 |
 Report Pages | 360 |
 By Product Type |
|
 By Procedure Type |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Terumo Corporation, Haemonetics Corporation, Fresenius SE & Co. KGaA, B.Braun SE, Medica SPA, Asahi Kasei Corporation, Baxter International Inc., Miltenyi Biotech, Becton, Dickinson and Company, Kaneka Corporation |
Analyst Review
This section provides various opinions of the therapeutic apheresis market. The rise in prevalence of chronic and autoimmune diseases is a key driver, increasing the demand for apheresis treatments to manage conditions such as rheumatoid arthritis, lupus, and myasthenia gravis. As a result, healthcare leaders must focus on investing in advanced apheresis technologies, such as automated and more efficient devices, to improve treatment outcomes and operational efficiencies. However, apheresis procedures are costly and require specialized equipment and skilled professionals, which can limit access in resource-constrained environments.
In addition, collaborations with research institutions to explore new indications for apheresis, including cancer and organ transplant management, can further fuel growth and innovation in the market. In addition, stronger healthcare policies that support the reimbursement of apheresis procedures reduces financial barriers for patients and healthcare providers. This increased financial support makes therapeutic apheresis treatments more accessible, leading to the market growth.
Furthermore, North America dominated the market share in 2023, in terms of revenue, owing to advanced healthcare infrastructure, high adoption of innovative medical technologies, and significant healthcare spending. The presence of leading hospitals and specialized treatment centers equipped with state-of-the-art apheresis devices further drives market expansion. However, Asia-Pacific is expected to register the highest CAGR during the forecast period, owing to rapid advancements in healthcare infrastructure, rise in investments in the medical sector, and rise in patient population with chronic and autoimmune diseases.
The total market value of herapeutic apheresis market was $1.3 billion in 2023.
The market value of therapeutic apheresis market is projected to reach $2.8 billion by 2035.
The forecast period for therapeutic apheresis market is 2024 to 2035.
Therapeutic apheresis is a medical procedure that involves the removal, treatment, and reinfusion of a patient’s blood to remove harmful substances or collect specific blood components for therapeutic purposes.
The base year is 2023 in therapeutic apheresis market.
North America led the market share in 2023, accounting for more than two-fifths of the share, driven by advanced healthcare infrastructure, high adoption rates, and favorable reimbursement policies.
Loading Table Of Content...
Loading Research Methodology...
